Menu
Search
|

Menu

Close
X

Omeros Corp OMER.OQ (NASDAQ Stock Exchange Global Market)

10.00 USD
+1.00 (+11.11%)
As of Feb 23
chart
Previous Close 9.00
Open 9.20
Volume 458,251
3m Avg Volume 260,052
Today’s High 10.17
Today’s Low 9.11
52 Week High 27.07
52 Week Low 8.66
Shares Outstanding (mil) 47.45
Market Capitalization (mil) 1,019.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
51
FY16
42
FY15
14
EPS (USD)
FY17
-0.832
FY16
-1.652
FY15
-2.000
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
19.01
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-192.07
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Gregory Demopulos
Chairman of the Board, President, Chief Executive Officer, Since 2013
Salary: $776,918.00
Bonus: $248,595.00
Michael Jacobsen
Chief Accounting Officer, Vice President - Finance, Treasurer, Since 2013
Salary: $336,778.00
Bonus: $51,880.00
Marcia Kelbon
Vice President - Patent, General Counsel, Secretary, Since 2007
Salary: $400,412.00
Bonus: $64,061.00
Thomas Cable
Lead Independent Director, Since 1995
Salary: --
Bonus: --
Peter Demopulos
Director, Since 1995
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

201 Elliott Ave W
SEATTLE   WA   98119-4240

Phone: +1206.6765000

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

SPONSORED STORIES